Yadana Kyaw, MD
Pulmonary Disease · Southaven, MSNPI 1134393473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 201 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$749
- Actelion Pharmaceuticals US, Inc.$694
- Insmed, Inc.$383
- Genentech USA, Inc.$367
- AstraZeneca$315
- Boehringer Ingelheim$279
- plus $916 from 19 others
What the payments were for
- Food & beverage$3,42392%
- Education$2808%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 44 | $749 |
| Actelion Pharmaceuticals US, Inc. | 44 | $694 |
| Insmed, Inc. | 17 | $383 |
| Genentech USA, Inc. | 10 | $367 |
| AstraZeneca | 19 | $315 |
| Boehringer Ingelheim | 15 | $279 |
| Sanofi | 9 | $197 |
| Harmony Biosciences LLC | 4 | $103 |
| Grifols USA, LLC | 5 | $77 |
| Electromed, Inc. | 6 | $70 |
| Novartis | 4 | $61 |
| Merck | 3 | $56 |
| Mylan Specialty L.p. | 3 | $51 |
| Amgen | 3 | $42 |
| United Therapeutics Corporation | 2 | $40 |
| Bayer | 2 | $36 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Advanced Respiratory, Inc | 2 | $26 |
| Gilead | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Ambu Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $12 |
How this compares
$3,703 in reported general payments places this provider in the 40th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 40 | $503,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $132,960 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $127,318 |
| XolairOmalizumab | 26 | $57,946 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $21,378 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $15,287 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,790 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,782 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,430 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,004 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,842 |
| Ventolin HfaAlbuterol Sulfate | 30 | $1,629 |
| Mycophenolate Mofetil | 18 | $934 |
| Gabapentin | 14 | $514 |
| Omeprazole | 23 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $279 | $524,76880 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $749 | $154,678203 claims |
| Grifols USA, LLCProlastin C | $77 | $127,31814 claims |
| AstraZenecaBreztri Aerosphere | $315 | $9,79016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Southaven
- Istvan WollakSouthaven$5K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Jaime UngoTupelo$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.